Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZL-82 Phase 1 in healthy volunteers
NCT06432738Phase 1Completed
- Sponsor
- Zenitar
- Start
- Mar 2024
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ZL-82 (8 arms), sponsored by Zenitar. Primary endpoints: Maximum Plasma Concentration at 72 hours, Time to Maximum Plasma Concentration at 72 hours and 6 more. Started Mar 2024; status: completed.
02
Drugs
ZL-82
Beyond the preview
Go deeper on NCT06432738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06432738.